Axa S.A. Supernus Pharmaceuticals, Inc. Transaction History
Axa S.A.
- $33.6 Billion
- Q2 2025
A detailed history of Axa S.A. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Axa S.A. holds 13,452 shares of SUPN stock, worth $760,038. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,452Holding current value
$760,038% of portfolio
0.0%Shares
12 transactions
Others Institutions Holding SUPN
# of Institutions
318Shares Held
61MCall Options Held
18.4KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$587 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.21MShares$351 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$272 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$171 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.76MShares$156 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $3.02B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...